Sonic Healthcare Limited

For H1 FY2026, Sonic Healthcare reported revenue of $5.445 billion, EBITDA of $907 million, net profit of $262 million, and EPS of AUD 0.531. Management said organic revenue growth was 5% overall, with Germany at 5% organic growth, Australia Pathology at 5%, the U.S. at 2% underlying organic growth after adjustments, Switzerland at 2%, the U.K. at 24%, Radiology at 7%, and Sonic Clinical Services at 5%. They said adjusted EBITDA margins were up 30 basis points versus H1 FY2025. Full-year guidance was maintained for EBITDA at $1.87 billion to $1.95 billion on a constant-currency basis, depreciation was guided to $770 million to $780 million, interest expense was guided to rise 15% year over year on a constant-currency basis, and the effective tax rate was guided at 27%. The interim dividend was declared at AUD 0.45, up 2.3% from the prior year, and 60% franked.

Jim Newcombe emphasized that Sonic’s medical leadership culture and operational discipline remain the core of the business. He repeatedly framed the quarter around organic growth, synergy capture, and margin accretion, saying EPS improvement and return on invested capital are top management priorities. He also struck an upbeat but measured tone on the U.S. review, saying it is an operating review focused on rationalizing underperforming anatomical pathology work rather than a strategic exit from the market.

Chris Wilks focused on balance-sheet strength, capital allocation, and the bridge from H1 to H2. He noted debt cover at 2.5x, headroom of $1 billion before the interim dividend, and net debt increases tied to the LADR Group and Cairo Diagnostics acquisitions. He said CapEx was elevated by property-related spending, including the Docklands site purchase of circa $100 million, and estimated second-half CapEx at roughly $20 million to $30 million, while maintenance CapEx excluding properties is around 3% to 3.5% of revenue. He also said the Bowen Hills sale-and-leaseback could carry circa $25 million of rent and that the company expects the first sale-and-leaseback process to launch early next week.

Analysts pressed on phlebotomist and health professional wage changes, and management said the phlebotomist impact for this year should be sub-$2 million, while the health professionals piece is still awaiting a Fair Work Commission determination and will not affect this financial year. There was also extensive questioning on the U.S. review: management said the work is focused on closing or rationalizing 9 anatomical pathology practices, improving collections, and leaning into advanced diagnostics, while acknowledging some restructuring costs will continue in H2 but should be de minimis. On Germany and Switzerland, management reaffirmed that synergies are on track, with LADR still targeted for an after-tax ROIC of about 11% within 3 years and the Swiss acquisitions tracking toward EBITDA margins around 20% over 3 years. Analysts also asked about FX and capital returns; management said FX remains a tailwind for the full year but a smaller one in H2, and that property-sale proceeds could support a future on-market buyback, subject to Board and capital-allocation considerations.